---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-008309"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:43:37.412937+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma receives Nasdaq bid price deficiency notice; 180-day cure period until June 5, 2023

## Summary
- Nasdaq notified SBFM on Dec 6, 2022 that bid price closed below $1.00 for 30 consecutive trading days.
- Company must regain compliance by June 5, 2023 by closing at $1.00+ for 10 consecutive business days.
- If not compliant by June 5, SBFM may qualify for an additional 180-day extension if it meets other listing standards.
- Company says it will monitor bid price and consider options including a reverse stock split.

## SEC filing metadata
- accession: 0001683168-22-008309
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316822008309/0001683168-22-008309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316822008309/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-008309
- JSON: https://secwatch.observer/filing/0001683168-22-008309.json
- Plain text: https://secwatch.observer/filing/0001683168-22-008309.txt

## Key facts
- Listing & Compliance Notices
  Sunshine Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: December 6, 2022, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no imm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316822008309/0001683168-22-008309-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.